Clinical Trial Search

Primary: Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo 24 Hours After Dosing — 1.48; -0.2 mg/mL

Primary: Composite Success — 16; 10; 10; 2 participants — p=<0.001

Primary: Clinical Safety--Creatinine Elevations — 0; 0 Participants

Primary: The Primary Objective of This Study is to Explore the Efficacy and Tolerability of DM-1992 Compared to a Standard CD/LD IR Formulation as Measured by Percent "OFF" Time…

Primary: Participants' Overall Satisfaction With the Drug Administration Experience Using the Physiolis Syringe/Autoinjector in Comparison to the Current Syringe/Autoinjector…

Primary: Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs) — 30…

Primary: Working Memory — 0.86; 0.04 digits recalled

Primary: Percentage of Participants With Reduction in Grade 3/4 Neutropenia — 40; 13 percentage of participants

Primary: Wolf Motor Function Test (Time) — 10.21; 29.69; 19.09; 26.05 units on a scale — p=<0.05

Primary: Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS) — 259.0; 39.4 scores on a scale

Primary: Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS) — 268.8; 230.9; 54.8 scores on a scale

Primary: Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analogue Scale (VAS) — 720.5; 239.9; 614.4; 450.8 scores on a scale

Primary: Mean Fecal Incontinence and Constipation Assessment (FICA) Score — 8.1; 9.1; 6.5; 7.6 units on a scale

Primary: Number of Participants With Adverse Events (AEs) — 2; 3; 0; 2 participants

Primary: Change in Insulin Resistance After 12 Weeks of Vitamin D3 Supplementation — 0.01; -0.27 HOMA score — p=0.95